Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 155

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 155
---
ors (together with their respective affiliates) may not exercise the warrants if the Investor would beneficially own more than 4.99%
or 9.99% (such amount to be determined at the option of the Investor upon issuance) of the number of Ordinary Shares outstanding immediately
after giving effect to such exercise. The July Purchase Agreement contains customary representations, warranties and covenants of the
Company and each Investor, and customary indemnification provisions for a transaction of this type. Pursuant to the terms of the July
Purchase Agreement, we agreed to be subject to a lock-up period on subsequent equity sales, which has since expired. We also agreed to
not issue any securities that are subject to a price reset based on the trading prices of our Ordinary Shares or upon a specified or contingent
event in the future or enter into any agreement to issue securities at a future determined price for a period of 180 days following the
closing date of the Offerings, subject to certain exceptions. Additionally, we agreed to reduce the exercise price of our existing Series
E warrants, Series G warrants and Series H warrants held by each Investor to $25.00 per Depositary Share.

In
connection with the Offerings, we entered into a Placement Agent Agreement with Ladenburg, pursuant to which we engaged Ladenburg as the
exclusive placement agent for the Offerings. We agreed to pay Ladenburg a cash fee in an amount equal to 8.0% of the aggregate gross proceeds
of the Offerings and to issue to Ladenburg or its designees the July 2024 Placement Agent Warrants. We also agreed to pay Ladenburg a
management fee equal to 1.0% of the gross proceeds raised in the Offerings and an expense allowance of up to $85,000 for legal fees and
other out-of-pocket expenses. The July 2024 Placement Agent Warrant has substantially the same terms as the Series J Warrants, except
that the exercise price of the July 2024 Placement Agent Warrants is $31.25 and the term of the July 2024 Placement Agent Warrants will
terminate on the three-year anniversary of the initial exercise date.

Warrant Inducement

On
May 22, 2024, we entered into Warrant Agreements with certain Holders that were holders of an aggregate of 62,906 of our outstanding Series
E Warrants exercisable for $55.00 per Depositary Share, and an aggregate of 61,275 of our outstanding